Standard BioTools (LAB) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Apr, 2026Executive summary
Annual meeting scheduled for June 17, 2026, with virtual participation available to shareholders.
Shareholders are encouraged to review proxy materials and annual report before voting.
Voting matters and shareholder proposals
Election of three Class I directors: Michael Egholm, Ph.D., Thomas Carey, and Eli Casdin.
Advisory vote on executive compensation (say-on-pay) for named executive officers.
Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2026.
Approval of the 2026 Equity Incentive Plan.
Amendment to the 2017 Employee Stock Purchase Plan to increase available shares by 1,200,000.
Board of directors and corporate governance
Board recommends voting in favor of all proposals, including director nominees and compensation plans.
Latest events from Standard BioTools
- Q3 2024 revenue was $45M, with improved margins and accelerated merger synergies.LAB
Q3 20248 Jul 2026 - Q1 2025 revenue fell 10% to $40.8M, but cost cuts and improved margins narrowed losses.LAB
Q1 20258 Jul 2026 - Cost synergies and consumables growth offset revenue declines, supporting a strong 2025 outlook.LAB
Q4 20248 Jul 2026 - All proposals passed, including director elections and equity plan approvals, with no Q&A.LAB
AGM 202617 Jun 2026 - All-stock merger forms a $900M+ cash biopharma with a deep pipeline and new leadership.LAB
M&A announcement8 Jun 2026 - Q1 2026 revenue grew 5% to $21.1M, with net income surging on a major asset sale.LAB
Q1 20266 May 2026 - 2026 meeting features director elections, key compensation votes, and new equity plan approval.LAB
Proxy filing27 Apr 2026 - 2025 revenue declined, but margins and net income improved, with strong cash post-divestiture.LAB
Q4 202524 Feb 2026 - Q2 revenue fell 23% YoY to $37.2M; cost synergies, cash, and leadership changes support outlook.LAB
Q2 20242 Feb 2026